Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL684285 | 0.89 | RXFP1 (0.53) | RXFP1LMNASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL683921 | 0.88 | RXFP1 (0.68) | RXFP1KDM4ETP53LMNASMN1; SMN2 | |
| SCHEMBL682774 | 0.88 | LMNA (0.66) | RXFP1LMNASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL684300 | 0.88 | ALDH1A1 (0.55) | RXFP1TP53LMNASMN1; SMN2MAPK1 | |
| Fenethylline SCHEMBL149145 | 0.87 | ALDH1A1 (0.65) | RXFP1LMNASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL683922 | 0.87 | CYP1A2 (0.61) | RXFP1TP53LMNASMN1; SMN2MAPK1 | |
| Fenethylline SCHEMBL155920 | 0.86 | ALDH1A1 (0.64) | RXFP1LMNASMN1; SMN2MAPK1ALDH1A1 | |
| Fenethylline SCHEMBL121386 | 0.86 | ALDH1A1 (0.64) | RXFP1LMNASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL683913 | 0.85 | RXFP1 (0.55) | RXFP1KDM4ETP53LMNASMN1; SMN2 | |
| SCHEMBL683986 | 0.84 | CYP1A2 (0.51) | RXFP1TP53LMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | RXFP1 211/4885KDM4E 2527/4885TP53 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.